

Immune profiling of advanced prostate cancer harbouring homologous recombination deficiency

Maryam Soleimani¹, Sonia Kung², Neetu Saxena², Marisa Thi², Ladan Fazli², Lucia Nappi^{1,2*}



• A p-value of <0.05 was defined as being statistically significant

This research was supported by the Prostate Cancer Foundation Young Investigator Award and the Michael Smith Foundation for Health and Research – Health Professional Investigator award (LN)

level. Bars indicate error bars.

¹ BC Cancer, Vancouver, British Columbia; ² Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia

*correspondence: maryam.soleimani@bccancer.bc.ca Abstract ID: 1784

For all poster figures: Immunoreactivity levels refer to the percentage of positively stained cells relative to all cells in prostate biopsy (as identified by nuclear counterstaining). Pvalues denoted by asterisks: () indicates $P \le 0.05$; (**) indicates $P \le 0.01$; (***) indicates $P \le 0.001$; (***) indicates $P \le 0.0001$. Red line indicates mean value of immunoreactivity



VANCOUVER

PROSTATE CENTRE

3C & VGH Centre of Excellence

phenotype selection criteria to improve stratification of existing immunotherapies, and those currently in development